Study of the Safety, Tolerability and Pharmacokinetics of TMB-607 in HIV-Negative Volunteers
Status:
Terminated
Trial end date:
2019-07-22
Target enrollment:
Participant gender:
Summary
The study is a Phase 1, randomized, double-blinded, placebo-controlled, sequential single
dose escalation safety, tolerability and pharmacokinetic study of subcutaneous and
intramuscular TMB-607 administered to HIV-negative volunteers.